Lenacapavir with optimised background regimen for treating multidrug resistant human immunodeficiency virus (HIV)-1 infection in people aged 12 years and older

Lenacapavir is in clinical development for the treatment of multidrug resistant (MDR) human
immunodeficiency virus (HIV)-1 infection in people who are heavily treatment-experienced. HIV
is caused by a virus that attacks the body’s immune system so that it is unable to sufficiently
respond to infections and illnesses. Without treatment, HIV can lead to the development of
acquired immune deficiency syndrome (AIDS), which is life-threatening. People with HIV show
flu-like symptoms two to six weeks after infection, after which they may be asymptomatic for
many years until HIV has significantly damaged the immune system, and the body struggles to
fight other illnesses and infections. Drug resistant HIV may be developed, as the virus mutates
slightly every replication, which can result in current treatments becoming ineffective.